{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:39:23Z","timestamp":1790091563887,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ard.2025.08.013","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T03:56:46Z","timestamp":1757735806000},"page":"412-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antiobesity medications in rheumatology. Quo vadis?"],"prefix":"10.1016","volume":"85","author":[{"given":"Niki","family":"Kyriazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos D.","family":"Vassilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Bakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexios","family":"Iliopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ard.2025.08.013_bib0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ard.2025.08.013_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.706978","article-title":"Obesity: epidemiology, pathophysiology, and therapeutics","volume":"12","author":"Lin","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ard.2025.08.013_bib0003","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ard.2025.08.013_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ard.2025.08.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241271886","article-title":"Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy","volume":"16","author":"Williams","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ard.2025.08.013_bib0006","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.08.013_bib0007","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3389\/fimmu.2014.00576","article-title":"Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases)","volume":"5","author":"Gremese","year":"2014","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.08.013_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"di Minno","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.ard.2025.08.013_bib0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1759720X18783894","article-title":"Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review","volume":"10","author":"Nikiphorou","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.08.013_bib0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.ard.2025.08.013_bib0011","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40618-024-02466-4","article-title":"Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network: author list","volume":"48","author":"Nassar","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"10.1016\/j.ard.2025.08.013_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0308533","article-title":"Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: a population-based study","volume":"19","author":"Karacabeyli","year":"2024","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ard.2025.08.013_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrrheum.2010.159","article-title":"The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis","volume":"6","author":"Sellam","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.08.013_bib0014","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.ard.2025.08.013_bib0015","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ard.2025.08.013_bib0016","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard-2023-223845","article-title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort","volume":"82","author":"Zhu","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.08.013_bib0017","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.ard.2025.08.013_bib0018","article-title":"Semaglutide-induced lupus erythematosus with multiorgan involvement","volume":"16","author":"Castellanos","year":"2024","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ard.2025.08.013_bib0019","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1093\/rheumatology\/keae547","article-title":"A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients","volume":"64","author":"Carlucci","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.08.013_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ard.2025.05.100","article-title":"OP0078 Comparing the impact of GLP-1 agonists and SGLT-2 inhibitors on outcomes in lupus nephritis: a retrospective cohort study","volume":"84","author":"Grzybowski","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.013_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103414","article-title":"Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases","volume":"153","author":"Yang","year":"2025","journal-title":"J Autoimmun"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.08.013_bib0022","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ard.2025.05.092","article-title":"OP0069 GLP1 agonists mitigate the risk of cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors","volume":"84","author":"Beltagy","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.08.013_bib0023","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ard.2025.05.291","article-title":"OP0281 Exploring GLP-1 agonists effects in fibromyalgia patients: a propensity matched analysis using TriNetX database","volume":"84","author":"Eshak","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.08.013_bib0024","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1210\/jc.2015-1176","article-title":"GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women","volume":"100","author":"Iepsen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ard.2025.08.013_bib0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bone.2015.08.006","article-title":"Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice","volume":"81","author":"Pereira","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.ard.2025.08.013_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.ard.2025.08.013_bib0027","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/ard-2023-224211","article-title":"Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease","volume":"84","author":"Deane","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.08.013_bib0028","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.08.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: a systematic review","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol Rev"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:26:27Z","timestamp":1786191987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725043122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0003496725043122"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.013","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiobesity medications in rheumatology. Quo vadis?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}